---
figid: PMC6914774__41392_2019_99_Fig1_HTML
figlink: /pmc/articles/PMC6914774/figure/Fig1/
number: F1
caption: There are several abnormal signaling and cell physiology-related pathways
  in lung cancer. Drugs targeting these abnormal pathways are depicted schematically.
  These drugs include agents specifically inhibiting components of the EGFR pathway
  and other family members and/or members of the VEGFR pathways. Other agents in development
  include inhibitors of the PI3K/AKT/mTOR pathway, the RAS/BRAF/MAPK pathway, and
  the JAK–STAT pathway.
pmcid: PMC6914774
papertitle: The emerging treatment landscape of targeted therapy in non-small-cell
  lung cancer.
reftext: Min Yuan, et al. Signal Transduct Target Ther. 2019;4:61.
pmc_ranked_result_index: '1707'
pathway_score: 0.9490281
filename: 41392_2019_99_Fig1_HTML.jpg
figtitle: The emerging treatment landscape of targeted therapy in non-small-cell lung
  cancer
year: '2019'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6914774__41392_2019_99_Fig1_HTML.html
  '@type': Dataset
  description: There are several abnormal signaling and cell physiology-related pathways
    in lung cancer. Drugs targeting these abnormal pathways are depicted schematically.
    These drugs include agents specifically inhibiting components of the EGFR pathway
    and other family members and/or members of the VEGFR pathways. Other agents in
    development include inhibitors of the PI3K/AKT/mTOR pathway, the RAS/BRAF/MAPK
    pathway, and the JAK–STAT pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - LILRB1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - HRAS
  - KRAS
  - NRAS
  - BRAF
  - PTEN
  - AKT2
  - AKT3
  - AKT1
  - MTOR
  - MAPK14
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK1
  - MAPK9
  - MAPK10
  - AMBP
  - gefitinib
  - erlotinib
  - Ruxolitinib
  - seluetinib
  - trametinib
  - LY294002
  - AP23573
  - Sorafenib
  - Temsirolimus
genes:
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: miR-7
  symbol: MIR-7
  source: hgnc_alias_symbol
  hgnc_symbol: LILRB1
  entrez: '10859'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: iti
  symbol: ITI
  source: hgnc_prev_symbol
  hgnc_symbol: AMBP
  entrez: '259'
chemicals:
- word: gefitinib
  source: MESH
  identifier: C419708
- word: erlotinib
  source: MESH
  identifier: C400278
- word: Ruxolitinib
  source: MESH
  identifier: C540383
- word: seluetinib
  source: ''
  identifier: ''
- word: trametinib
  source: MESH
  identifier: C560077
- word: LY294002
  source: MESH
  identifier: C085911
- word: AP23573
  source: ''
  identifier: ''
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Temsirolimus
  source: MESH
  identifier: C401859
diseases: []
figid_alias: PMC6914774__F1
redirect_from: /figures/PMC6914774__F1
figtype: Figure
---
